EORTC STBSG

Information about EORTC STBSG

Published on November 1, 2007

Author: Goldye

Source: authorstream.com

Content

EORTC STBSG:  EORTC STBSG Ongoing clinical trials Venice, November 4th Slide2:  A RANDOMIZED STUDY COMPARING NEOADJUVANT CHEMOTHERAPY ETOPOSIDE + IFOSFAMIDE + ADRIAMYCIN (EIA) COMBINED WITH REGIONAL HYPERTHERMIA (RHT) VS. NEOADJUVANT CHEMOTHERAPY ALONE IN THE TREATMENT OF HIGH-RISK SOFT TISSUE SARCOMAS IN ADULTS AN INTERGROUP STUDY WITH THE EUROPEAN SOCIETY FOR HYPERTHERMIC ONCOLOGY PROTOCOL 62981: Randomized Phase III study to evaluate the role of high dose chemotherapy intensification in the treatment of intermediate prognosis Ewing’s sarcoma and Primitive Neuroectodermal Tumour (PNET):  PROTOCOL 62981: Randomized Phase III study to evaluate the role of high dose chemotherapy intensification in the treatment of intermediate prognosis Ewing’s sarcoma and Primitive Neuroectodermal Tumour (PNET) Stratification: Age Local trt of primary VIDE: Vincristine Ifosfamide Doxorubicin Etoposide VAI: Vincristine Actinomycin Ifosfamide VAC: Vincristine Actinomycin D Cyclophosphamide Bu-mel: Busulfan Melphalan Study Coordinator: I. Judson, London Eligibility: Ewing/PNET < 50 years No previous chemo PROTOCOL 62991-22998: Phase II study of moderate dose radiotherapy for inoperable aggressive fibromatosis:  PROTOCOL 62991-22998: Phase II study of moderate dose radiotherapy for inoperable aggressive fibromatosis Study coordinator: Ronald KEUS, Arnhem Eligibility: Histologically confirmed aggressive fibromatosis Measurable disease (RECIST) No current endocrine or chemotherapy, no prior or concurrent limb perf with TNF >15 years PROTOCOL 62991-22998: ACCRUAL GRAPH:  PROTOCOL 62991-22998: ACCRUAL GRAPH PROTOCOL 62012: Randomized trial of single agent doxorubicin versus doxorubicin plus ifosfamide :  PROTOCOL 62012: Randomized trial of single agent doxorubicin versus doxorubicin plus ifosfamide Stratification: Age (<50 vs ≥50) PS (0 vs 1) Liver mets (0 vs +) Histological grade (2 vs 3) Study Coordinator: I. Judson, London Eligibility: High grade STS (2-3) Age 16-60 No previous chemo for adv/met dis WHO PS < 2 Slide11:  Study 62012: accrual on 30/10 204 patients PROTOCOL 62022: Phase II study of Iressa (ZD1839) in locally advanced and/or metastatic synovial sarcoma:  PROTOCOL 62022: Phase II study of Iressa (ZD1839) in locally advanced and/or metastatic synovial sarcoma ZD1839 500 mg/day orally once a day for at least 52 weeks Study Coordinator: J-Y Blay, Lyon Eligibility: Advanced/metastatic synovial sarcoma expressing HER1 Ag (DAKO or another mAb) Frozen tissue available for genetic confirmation of the diagnosis and molecular anal. One previous line of chemotherapy containing doxorubicin and/or ifosfamide PROTOCOL 62024: Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery :  PROTOCOL 62024: Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery Stratification: Risk category Tumour site Resection level Study Coordinators: P. CASALI, Milan (ISG) and J-Y BLAY, Lyon (EORTC STBSG) Eligibility: GIST with positive immunostaining for KIT Risk of relapse documented on surgical specimen No evidence of residual macroscopic disease after surg No distant metastases WHO PS 0-2, age >17 No prior radiation therapy /chemotherapy After complete surgery Main endpoint: Overall survival Secondary endpoints: Relapse-free survival Relapse-free interval toxicity Collaborating Groups: ISG, FSG, EORTC STBSG, GEIS, AGITG PROTOCOL 62024: Accrual by Group:  PROTOCOL 62024: Accrual by Group PROTOCOL 62024: Stratification factors:  PROTOCOL 62024: Stratification factors PROTOCOL 62027: Phase II study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcoma expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF-beta fusion protein i.e DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF).:  PROTOCOL 62027: Phase II study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcoma expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF-beta fusion protein i.e DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF). GLIVEC 400 mg bid for at least 14 weeks Study Coordinator: A.T. Van Oosterom, Leuven Eligibility: Histologically proven locally advanced or metastatic DFSP or GCF Progressive disease documented in the last 3 months Disease not amenable to surgery, radiation or combined modality treatment with curative intent Frozen tumor or paraffin embedded tissue available for immunohistochemical, molecular analysis and central path. review No prior chemotherapy or no more than 1 line combination chemo with Ifosfamide and Doxorubicin or 2 lines of single agent therapy or relapsing within 6 months after end of adjuvant chemo. WHO PS 0-2, age 18 years or more 62027 Accrual:  62027 Accrual Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma:  Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma EORTC study 62043 Accrual graph (cut-off 11 Oct ’06):  Accrual graph (cut-off 11 Oct ’06) Phase II study of E7389 administered as an IV infusion day 1 and 8 every 3 weeks in pretreated patients with advanced and/or metastatic soft tissue sarcoma :  Phase II study of E7389 administered as an IV infusion day 1 and 8 every 3 weeks in pretreated patients with advanced and/or metastatic soft tissue sarcoma EORTC study 62052 Trial 62052 :  Trial 62052 Study Coordinator : Dr. Patrick Schoeffski (Leuven, Belgium) Date of PRC protocol approval: July 17, 2006 Version and date of last amendment: first amendment (non-substantial) protocol version 1.1, August 8, 2006 Treatment scheme : Intravenous bolus of E7389 (1.4 mg/m²) on days 1 and 8 every 21 days Sample size :  Sample size The trial will be independently conducted in 4 groups of patients (strata) : Leiomyosarcoma Liposarcoma Synovial sarcoma Other types of eligible STS STEP 1: 17 eligible patients per stratum STEP 2: if > 3 successes in step 1 : continue up to 37 eligible patients per stratum Randomized Phase II study of brostacillin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma :  Randomized Phase II study of brostacillin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma EORTC study 62061 Study Coordinator : Dr. Hans Gelderblom Trial 62061 :  Trial 62061 Date of PRC protocol approval : June 29, 2006 Treatment scheme : max 6 cycles treatment ARM A : Brostallicin 10 min. IV infusion (10 mg/m²) on day 1 of a q3w cycle (12.5 mg/m² from second cycle in case of good tolerance) ARM B : Doxorubicin IV bolus (75 mg/m²) on day 1 of a q3w cycle Sample Size : 72 (brostacillin) + 36 (doxorubicin) Eligibility :  Main eligibility criteria : Histological or cytological confirmed high or intermediate grade malignant soft tissue sarcoma Objective documentation of disease progression within the last 6 months. Relapsed or refractory disease incurable by surgery or radiotherapy. Presence of measurable disease (RECIST). No prior chemotherapy regimen for advanced or metastatic disease; (neo)adjuvant therapy is allowed. At least 60 years of age, or patients at least 18 years of age non suitable for intensive chemotherapy combination treatments WHO performance status 0 or 1 Adequate bone marrow, hepatic and renal function Eligibility End-Points:  End-Points Primary: 6 months progression-free survival (assessed at 26 weeks) Secondary: Overall progression-free survival Overall survival Objective tumor response (RECIST) Duration of response Participating countries:  Participating countries Belgium (3) UK (6) France (3) The Netherlands (5) Poland (1) 26 sites in 7 countries Germany (7) Slovakia (1) CA & EC approval CA & EC approval EC approval

Related presentations


Other presentations created by Goldye

La Leccion de la Mariposa 2143
19. 06. 2007
0 views

La Leccion de la Mariposa 2143

seo july06
04. 09. 2007
0 views

seo july06

fairy tales
26. 10. 2007
0 views

fairy tales

INTERNET TECHNOLOGIES
19. 06. 2007
0 views

INTERNET TECHNOLOGIES

encrypt sign
16. 06. 2007
0 views

encrypt sign

1006969221 presentation brazil2
21. 09. 2007
0 views

1006969221 presentation brazil2

chauce3b
01. 10. 2007
0 views

chauce3b

1 Performance
07. 10. 2007
0 views

1 Performance

Swiss LifeScience Survey 2006
15. 10. 2007
0 views

Swiss LifeScience Survey 2006

Xray Lecture01
16. 10. 2007
0 views

Xray Lecture01

PAL MOR
23. 10. 2007
0 views

PAL MOR

kidd
04. 09. 2007
0 views

kidd

svn
29. 11. 2007
0 views

svn

kuznetsov evgeny ppt ai seminar
26. 10. 2007
0 views

kuznetsov evgeny ppt ai seminar

MotherGoose
02. 11. 2007
0 views

MotherGoose

cewit
04. 09. 2007
0 views

cewit

primitive
15. 11. 2007
0 views

primitive

vision02
20. 11. 2007
0 views

vision02

The Art of Living
22. 11. 2007
0 views

The Art of Living

Zambia
04. 09. 2007
0 views

Zambia

Predation lecture Nov30 no2
30. 12. 2007
0 views

Predation lecture Nov30 no2

Launching the New Deal
31. 12. 2007
0 views

Launching the New Deal

prosperity
03. 01. 2008
0 views

prosperity

Machine Guarding
07. 01. 2008
0 views

Machine Guarding

Global Lessons Geneva2
07. 08. 2007
0 views

Global Lessons Geneva2

maldives accredit board
07. 08. 2007
0 views

maldives accredit board

Bernie sPP
07. 08. 2007
0 views

Bernie sPP

Labor
07. 08. 2007
0 views

Labor

OzCHI
07. 08. 2007
0 views

OzCHI

SCLC
03. 01. 2008
0 views

SCLC

culling elephants1
04. 09. 2007
0 views

culling elephants1

ch 15
04. 01. 2008
0 views

ch 15

UNDP
07. 08. 2007
0 views

UNDP

MDA Maldives
07. 08. 2007
0 views

MDA Maldives

attach28
10. 10. 2007
0 views

attach28

Cindy Zheng PRAGMA grid v3
09. 10. 2007
0 views

Cindy Zheng PRAGMA grid v3

Home COMBI workshop
07. 08. 2007
0 views

Home COMBI workshop

OHSWildlifeHandlersW EB
19. 11. 2007
0 views

OHSWildlifeHandlersW EB

Amazed
27. 11. 2007
0 views

Amazed

Panama MWG 29Jun06
22. 10. 2007
0 views

Panama MWG 29Jun06

erasmus mundus presentation
21. 03. 2008
0 views

erasmus mundus presentation

Special Topics 950414
07. 04. 2008
0 views

Special Topics 950414

program 1a 1c
04. 10. 2007
0 views

program 1a 1c

Korea Outlook
28. 03. 2008
0 views

Korea Outlook

Japan08
30. 03. 2008
0 views

Japan08

RabbitsCowsDaVinci
05. 01. 2008
0 views

RabbitsCowsDaVinci

CB05Chapter6
09. 04. 2008
0 views

CB05Chapter6

mobilanalysis
10. 04. 2008
0 views

mobilanalysis

nd planning brief
13. 04. 2008
0 views

nd planning brief

Interestrt
14. 04. 2008
0 views

Interestrt

interim2004
17. 04. 2008
0 views

interim2004

the final1
17. 04. 2008
0 views

the final1

IUM dec2007
22. 04. 2008
0 views

IUM dec2007

kumar friart
15. 10. 2007
0 views

kumar friart

ideaz first consulting
19. 06. 2007
0 views

ideaz first consulting

I2TK
19. 06. 2007
0 views

I2TK

Humor Grafico Informatica 1723
19. 06. 2007
0 views

Humor Grafico Informatica 1723

Grecia Italia 2136
19. 06. 2007
0 views

Grecia Italia 2136

Carta de Jesus 2014
19. 06. 2007
0 views

Carta de Jesus 2014

APP The American Experience WK 5
14. 12. 2007
0 views

APP The American Experience WK 5

Postwar World
20. 02. 2008
0 views

Postwar World

La France 2140
19. 06. 2007
0 views

La France 2140

Increibles pero ciertas 2138
19. 06. 2007
0 views

Increibles pero ciertas 2138

I Know Something Good About You
19. 06. 2007
0 views

I Know Something Good About You

FinanceWkshop Oct06
29. 09. 2007
0 views

FinanceWkshop Oct06

truck
28. 02. 2008
0 views

truck

CPAC2006 StrawPoll
19. 06. 2007
0 views

CPAC2006 StrawPoll

contenzioso
19. 06. 2007
0 views

contenzioso

catalogo2007
19. 06. 2007
0 views

catalogo2007

castello
19. 06. 2007
0 views

castello

A SSCC2007Feb07
09. 10. 2007
0 views

A SSCC2007Feb07

ch11 sec2
25. 03. 2008
0 views

ch11 sec2

pressyn
10. 10. 2007
0 views

pressyn

Condones a la medida 1712
19. 06. 2007
0 views

Condones a la medida 1712

La capa verde 1852
19. 06. 2007
0 views

La capa verde 1852

Introduzione COAN in PMI
19. 06. 2007
0 views

Introduzione COAN in PMI

Indigena 2078
19. 06. 2007
0 views

Indigena 2078

Geno Pro
16. 06. 2007
0 views

Geno Pro

Exchange
16. 06. 2007
0 views

Exchange

Exchange Office
16. 06. 2007
0 views

Exchange Office

Excel 03
16. 06. 2007
0 views

Excel 03

eLearning An OverviewV2
16. 06. 2007
0 views

eLearning An OverviewV2

dpa foi
16. 06. 2007
0 views

dpa foi

24 Horas 2087
19. 06. 2007
0 views

24 Horas 2087

Creazione Sito Web
19. 06. 2007
0 views

Creazione Sito Web

convegno
19. 06. 2007
0 views

convegno

IRREBULL05
19. 06. 2007
0 views

IRREBULL05

present cartagena
22. 10. 2007
0 views

present cartagena

oct city hudco
01. 01. 2008
0 views

oct city hudco

5 Judios 2088
19. 06. 2007
0 views

5 Judios 2088

Plan Puebla Panama
22. 10. 2007
0 views

Plan Puebla Panama

Empyrean Code Master Challenge
16. 06. 2007
0 views

Empyrean Code Master Challenge

cm1 2002 ziegele3
19. 06. 2007
0 views

cm1 2002 ziegele3

IAEC Training
19. 06. 2007
0 views

IAEC Training

west ldc
04. 09. 2007
0 views

west ldc

11 WR USSR
03. 10. 2007
0 views

11 WR USSR

Thrombophilia
07. 08. 2007
0 views

Thrombophilia

Calendar3 20 07
19. 06. 2007
0 views

Calendar3 20 07

ctrl Mela Oven
19. 06. 2007
0 views

ctrl Mela Oven

Butcher
04. 09. 2007
0 views

Butcher